BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 12587122)

  • 1. Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets.
    Siegmund W; Ludwig K; Engel G; Zschiesche M; Franke G; Hoffmann A; Terhaag B; Weitschies W
    J Pharm Sci; 2003 Mar; 92(3):604-10. PubMed ID: 12587122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-glycoprotein and surfactants: effect on intestinal talinolol absorption.
    Bogman K; Zysset Y; Degen L; Hopfgartner G; Gutmann H; Alsenz J; Drewe J
    Clin Pharmacol Ther; 2005 Jan; 77(1):24-32. PubMed ID: 15637528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans.
    Tubic M; Wagner D; Spahn-Langguth H; Weiler C; Wanitschke R; Böcher WO; Langguth P
    Eur J Pharm Sci; 2006 Nov; 29(3-4):231-9. PubMed ID: 16713700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of continuous glycyrrhizin administration on the pharmacokinetics of the P-glycoprotein substrate talinolol in healthy volunteers.
    Yan M; Fang PF; Li HD; Xu P; Liu YP; Wang F; Cai HL; Tan QY
    Eur J Clin Pharmacol; 2013 Mar; 69(3):515-21. PubMed ID: 22983284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein.
    Westphal K; Weinbrenner A; Giessmann T; Stuhr M; Franke G; Zschiesche M; Oertel R; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Jul; 68(1):6-12. PubMed ID: 10945310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
    Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
    Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.
    Okyar A; Dressler C; Hanafy A; Baktir G; Lemmer B; Spahn-Langguth H
    Chronobiol Int; 2012 May; 29(4):443-53. PubMed ID: 22489638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
    Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
    Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability of two oral-tablet and two oral-suspension formulations of naproxen sodium/paracetamol (acetaminophen): single-dose, randomized, open-label, two-period crossover comparisons in healthy Mexican adult subjects.
    Palma-Aguirre JA; Villalpando-Hernández J; Novoa-Heckel G; Oliva I; Cariño L; López-Bojórquez E; Burke-Fraga V; Namur S; González-de la Parra M
    Clin Ther; 2009 Feb; 31(2):399-410. PubMed ID: 19302912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms.
    Bernsdorf A; Giessmann T; Modess C; Wegner D; Igelbrink S; Hecker U; Haenisch S; Cascorbi I; Terhaag B; Siegmund W
    Br J Clin Pharmacol; 2006 Apr; 61(4):440-50. PubMed ID: 16542205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans.
    Gramatté T; Oertel R; Terhaag B; Kirch W
    Clin Pharmacol Ther; 1996 May; 59(5):541-9. PubMed ID: 8646825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
    Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of curcumin on the pharmacokinetics of talinolol in human with ABCB1 polymorphism.
    He X; Mo L; Li ZY; Tan ZR; Chen Y; Ouyang DS
    Xenobiotica; 2012 Dec; 42(12):1248-54. PubMed ID: 22725663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No sex difference in overall P-glycoprotein activity as assessed by talinolol disposition in humans.
    Long B; Su YQ; Xia Y; Zou YY; Tang B; Chen ZJ; Lin Y
    Int J Clin Pharmacol Ther; 2016 Mar; 54(3):157-62. PubMed ID: 26784939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
    Westphal K; Weinbrenner A; Zschiesche M; Franke G; Knoke M; Oertel R; Fritz P; von Richter O; Warzok R; Hachenberg T; Kauffmann HM; Schrenk D; Terhaag B; Kroemer HK; Siegmund W
    Clin Pharmacol Ther; 2000 Oct; 68(4):345-55. PubMed ID: 11061574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative bioavailability and pharmacokinetics of investigational enteric- and film-coated formulations of flurbiprofen 100-mg tablets: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Pakistani male volunteers.
    Ahmad M; Pervaiz F
    Clin Ther; 2010 Mar; 32(3):607-13. PubMed ID: 20399997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico modeling of non-linear drug absorption for the P-gp substrate talinolol and of consequences for the resulting pharmacodynamic effect.
    Tubic M; Wagner D; Spahn-Langguth H; Bolger MB; Langguth P
    Pharm Res; 2006 Aug; 23(8):1712-20. PubMed ID: 16832615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.